Isomorphic Labs, an AI drug design firm based in London, successfully raised $600 million in its first external funding round, led by Thrive Capital and supported by GV (Google Ventures). The company, founded in 2021 by Sir Demis Hassabis, aims to revolutionize drug discovery through advanced AI technologies, which allow researchers to explore chemical possibilities and address challenging targets more efficiently. As a spin-off from Alphabet's Google DeepMind, its team is experienced in cutting-edge AI research, notably in protein structure prediction with AlphaFold, positioning Isomorphic Labs at the forefront of a new era in drug design.
We believe Isomorphic has earned a rare position to define a new age of drug discovery and design, and we are deeply inspired by their mission.
AI and machine learning have long held the promise of transforming drug discovery, yet few companies over the past decade have unlocked their full potential.
Collection
[
|
...
]